Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study)

被引：0
|
作者：
Hiroki Nakajima
Sadanori Okada
Takako Mohri
Eiichiro Kanda
Naoyuki Inaba
Yoko Hirasawa
Hiroaki Seino
Hisamoto Kuroda
Toru Hiyoshi
Tetsuji Niiya
Hitoshi Ishii
机构：
[1] Nara Medical University,Department of Diabetology
[2] Tokyo Kyosai Hospital,Department of Nephrology
[3] Tokyo Medical and Dental University,Life Science and Bioethics Research Center
[4] Shizuoka Saiseikai General Hospital,Department of Metabolism & Endocrinology
[5] Plumeria DM Clinic,Department of Internal Medicine
[6] Seino Internal Medicine Clinic,undefined
[7] Green Clinic,undefined
[8] Japanese Red Cross Medical Center,undefined
[9] Matsuyama Shimin Hospital,undefined
来源：
Diabetology & Metabolic Syndrome | / 10卷
关键词：
Type 2 diabetes mellitus; Oral hypoglycemic agent; Sodium glucose cotransporters 2 inhibitors; SGLT2 inhibitors; Dapagliflozin; Treatment satisfaction; Oral Hypoglycemic Agent-Questionnaire; Body weight; Patient reported outcome; Quality of life;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [11] Semaglutide improves treatment satisfaction and eating behaviour in Japanese patients with type 2 diabetes mellitus
    Baba, Yusuke
    Watanabe, Suzuka
    Hayashi, Saho
    Sakai, Toshiki
    Naka, Masamitsu
    Kami, Saori
    Hirayama, Kiichi
    Koizumi, Kazuko
    Takahashi, Ai
    Meguro, Miwako
    Iga, Ryo
    Yamanaka, Yoshitaka
    Kataoka, Masaaki
    Uchida, Daigaku
    Ishibashi, Ryoichi
    DIABETES OBESITY & METABOLISM, 2024, 26 (10): : 4787 - 4790
  • [12] Clinical characteristics and patient treatment satisfaction with Humalog U-200 in patients with type 2 diabetes mellitus: an observational study
    Mamza, Jil
    Anyanwagu, Uchena
    Alkharaiji, Mohammed
    Idris, Iskandar
    JOURNAL OF DRUG ASSESSMENT, 2020, 9 (01) : 8 - 12
  • [13] Dapagliflozin treatment for type 2 diabetes mellitus patients with a history of cardiovascular disease
    Leiter, L.
    Cefalu, W.
    DeBruin, T.
    Gause-Nilsson, I.
    Sugg, J.
    Parikh, S.
    DIABETOLOGIA, 2012, 55 : S310 - S311
  • [14] Use and effectiveness of dapagliflozin in patients with type 2 diabetes mellitus: a multicenter retrospective study in Taiwan
    Chen, Jung-Fu
    Peng, Yun-Shing
    Chen, Chung-Sen
    Tseng, Chin-Hsiao
    Chen, Pei-Chi
    Lee, Ting-, I
    Lu, Yung-Chuan
    Yang, Yi-Sun
    Lin, Ching-Ling
    Hung, Yi-Jen
    Chen, Szu-Ta
    Lu, Chieh-Hsiang
    Yang, Chwen-Yi
    Chen, Ching-Chu
    Lee, Chun-Chuan
    Hsiao, Pi-Jung
    Jiang, Ju-Ying
    Tu, Shih-Te
    PEERJ, 2020, 8
  • [15] Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus in China: Results from the DONATE Study
    Guo, Lixin
    Wang, Jing
    Li, Li
    Yuan, Lin
    Chen, Sheng
    Wang, Hui
    Li, Tonghuan
    Qi, Lin
    Yang, Hong
    DIABETES, 2022, 71
  • [16] Quality of life and treatment satisfaction are highly relevant patient-reported outcomes in type 2 diabetes mellitus
    Mauricio, Didac
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (11)
  • [17] Safety and Efficacy of Dapagliflozin in Lean vs. Overweight Asian Patients with Type 2 Diabetes Mellitus
    Zhou, Zhiguang
    Kim, Sin Gon
    Sjostrom, David
    Johnsson, Kristina M.
    Johnsson, Eva
    DIABETES, 2015, 64 : A653 - A653
  • [18] Efficacy and safety of dapagliflozin and liraglutide in patients with type 2 diabetes mellitus and newly diagnosed as overweight/obese
    Liang, Yan-Ling
    Chen, Ling
    Wang, Tong
    Qu, Jian-Chang
    ASIAN JOURNAL OF SURGERY, 2023, 46 (02) : 1000 - 1001
  • [19] Dapagliflozin: An emerging treatment option for type 2 diabetes mellitus
    Lu, Jessica
    Ta, Elisa
    Song, Jessica C.
    FORMULARY, 2011, 46 (10) : 412 - +
  • [20] Dapagliflozin improves erectile dysfunction in patients with type 2 diabetes mellitus: An open-label, non-randomized pilot study
    Cannarella, Rossella
    Condorelli, Rosita A.
    Leanza, Claudia
    Garofalo, Vincenzo
    Aversa, Antonio
    Papa, Giuseppe
    Calogero, Aldo E.
    La Vignera, Sandro
    DIABETIC MEDICINE, 2024, 41 (01)
12345